In our study, the significantly higher expression of immune checkpoint genes, including PDL1, PD1, and CTLA4, and elevation of the point mutation rate of TP53 were found in high-TR-DDR score groups, which indicated that mutations of DDR genes in a tumor might influence treatment efficacy through altering expression levels of immune checkpoint molecules (Figure 6). Here, CTLA4 is linked to neoplasm.